Feb 27, 2024 08:05AM
Feb 27, 2024 08:00AM
Nov 2, 2023 07:00AM
Aug 3, 2023 07:00AM
Jun 5, 2023 07:00AM
May 16, 2023 07:04AM
May 16, 2023 07:00AM AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer
May 4, 2023 07:00AM
Apr 26, 2023 07:00AM
Apr 26, 2023 07:00AM
Feb 23, 2023 04:16PM
Feb 23, 2023 04:15PM
Feb 15, 2023 07:07AM
Feb 15, 2023 07:00AM AlloVir (ALVR) Reports Positive Final Results from Phase 2 Study of Posoleucel
Feb 15, 2023 07:00AM
Jan 9, 2023 07:00AM
Dec 10, 2022 05:15PM
Nov 3, 2022 09:07AM
Nov 3, 2022 07:00AM
Aug 4, 2022 07:00AM
Jul 27, 2022 07:00AM AlloVir (ALVR) Announces 27.5M Share Offering at $4.61/sh
Jul 27, 2022 07:00AM
Jun 7, 2022 08:32AM
Jun 7, 2022 08:30AM
May 5, 2022 07:00AM
Apr 20, 2022 09:23AM
Apr 20, 2022 07:20AM
Apr 20, 2022 07:00AM AlloVir (ALVR) Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel
Apr 20, 2022 07:00AM
Mar 31, 2022 07:02AM
Mar 31, 2022 07:00AM
Mar 22, 2022 07:00AM
Feb 10, 2022 07:00AM
Jan 5, 2022 07:30AM
Jan 5, 2022 07:30AM FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transpl
Dec 13, 2021 05:15AM
Dec 11, 2021 01:00PM
Dec 2, 2021 04:05PM
Nov 5, 2021 07:00AM
Oct 4, 2021 07:03AM
Oct 4, 2021 07:00AM
Sep 29, 2021 07:00AM Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir’s Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta
Aug 6, 2021 07:00AM
May 6, 2021 07:00AM
Mar 22, 2021 04:01PM
Mar 22, 2021 04:00PM
Feb 11, 2021 04:00PM
Feb 11, 2021 07:00AM
Jan 11, 2021 01:52PM AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
Dec 17, 2020 07:32AM

322,242 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All